From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 15, 2023
Expiration Date: March 15, 2024
Description:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid lineage cells, splenomegaly, and risk of hemorrhagic and thrombotic sequelae. JAK kinase inhibitors have transformed treatment paradigms for patients with myelofibrosis, and integrating these and other targeted agents with allogenic transplant and symptom-mitigating strategies is essential when managing patients, especially those with higher risk disease.
This online, on-demand virtual symposium is an ancillary to the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR and brings together renowned experts to highlight clinical trial evidence behind current standards of care as well as emerging studies investigating the role of JAK inhibitors and allogeneic transplant in the treatment of myelofibrosis. Faculty experts discuss community perspectives in prerecorded, real-world videos.
This educational activity is an archive of the live symposium held on February 17, 2023.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Determine patient- and disease-related features that inform the diagnosis, risk assessment, and treatment/transplantation eligibility to manage patients with myelofibrosis (MF)
• Assess the therapeutic roles of JAK inhibitors and other emerging therapies in the peritransplant setting for the management of patients with MF
• Report trial evidence on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options in the care of transplant-eligible and -ineligible patients with MF
• Apply strategies concerning first- and second-generation JAK inhibitors in peritransplant MF settings, and evidence that informs sequencing of these agents in non-HSCT settings.